Phosphodiesterase 4 inhibition enhances the dopamine D1 receptor/PKA/DARPP-32 signaling cascade in frontal cortex
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Alteration of dopamine neurotransmission in the prefrontal cortex, especially hypofunction of dopamine D1 receptors, contributes to psychotic symptoms and cognitive deficit in schizophrenia. D1 receptors signal through the cAMP/PKA second messenger cascade, which is modulated by phosphodiesterase (PDE) enzymes that hydrolyze and inactivate cyclic nucleotides. Though several PDEs are expressed in cortical neurons, the PDE4 enzyme family (PDE4A-D) has been implicated in the control of cognitive function. The best studied isoform, PDE4B, interacts with a schizophrenia susceptibility factor, disrupted in schizophrenia 1 (DISC1). We explore the control of mouse frontal cortex dopamine D1 receptor signaling and associated behavior by PDE4. Inhibition of PDE4 by rolipram induced activation of cAMP/PKA signaling in cortical slices and in vivo, leading to the phosphorylation of DARPP-32 and other postsynaptic and presynaptic PKA-substrates. Rolipram also enhanced DARPP-32 phosphorylation invoked by D1 receptor activation. Immunohistochemical studies demonstrated PDE4A, PDE4B, and PDE4D expression in DARPP-32-positive neurons in layer VI of frontal cortex, most likely in D1 receptor-positive, glutamatergic corticothalamic pyramidal neurons. Furthermore, the ability of rolipram treatment to improve the performance of mice in a sensorimotor gating test was DARPP-32-dependent. PDE4, which is co-expressed with DARPP-32 in D1 receptor-positive cortical pyramidal neurons in layer VI, modulates the level of D1 receptor signaling and DARPP-32 phosphorylation in the frontal cortex, likely influencing cognitive function. These biochemical and behavioral actions of PDE4 inhibitors may contribute to the hypothesized antipsychotic actions of this class of compounds.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Geyer, M. A., Krebs-Thomson, K., Braff, D. L., & Swerdlow, N. R. (2001) · Psychopharmacology · doi:10.1007/s002130100811 · Cited by 1,484
D1 Dopamine Receptors in Prefrontal Cortex: Involvement in Working Memory
Sawaguchi, T., & Goldman-Rakic, P. S. (1991) · Science · doi:10.1126/science.1825731 · Cited by 1,364
Characterization of multiple phosphorylation sites on the AMPA receptor GluR1 subunit
Roche, K. W., O'Brien, R. J., Mammen, A. L., Bernhardt, J., & Huganir, R. L. (1996) · Neuron · doi:10.1016/s0896-6273(00)80144-0 · Cited by 812
DISC1 and PDE4B Are Interacting Genetic Factors in Schizophrenia That Regulate cAMP Signaling
Millar, J. K., Pickard, B. S., Mackie, S., James, R., Christie, S., Buchanan, S. R., Malloy, M. P., Chubb, J. E., Huston, E., Baillie, G. S., et al. (2005) · Science · doi:10.1126/science.1112915 · Cited by 648
Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction
Goldman-Rakic, P., Castner, S., Svensson, T., Siever, L., & Williams, G. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1793-y · Cited by 544 · cited 1×
“As an integral component of the mesolimbic system, the PFC receives dopaminergic projections from the ventral tegmental area, and activation of cortical dopamine D1 receptors improves cognition (Ehrman et al. 2006; Goldman-Rakic et al. 2004).”
The DISC locus in psychiatric illness
Chubb, J. E., Bradshaw, N. J., Soares, D. C., Porteous, D. J., & Millar, J. K. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002106 · Cited by 542
Behavioral phenotypes of Disc1 missense mutations in mice
Clapcote, S. J., Lipina, T. V., Millar, J. K., Mackie, S., Christie, S., Ogawa, F., Lerch, J. P., Trimble, K., Uchiyama, M., Sakuraba, Y., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.04.015 · Cited by 526
Tyrosine hydroxylase phosphorylation: Regulation and consequences
Dunkley, P. R., Bobrovskaya, L., Graham, M. E., Von Nagy‐Felsobuki, E. I., & Dickson, P. W. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02797.x · Cited by 455 · cited 2×
“Phosphorylation of TH, the rate-limiting enzyme in dopamine biosynthesis which is abundant in catecholaminergic nerve terminals, at Ser40 is known to play an important role in the synthesis of dopamine (Dunkley et al. 2004; Harada et al. 1996).”
Swerdlow, N. R., Light, G. A., Cadenhead, K. S., Sprock, J., Hsieh, M. H., & Braff, D. L. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.12.1325 · Cited by 339
Ralph, R. J., Paulus, M. P., Fumagalli, F., Caron, M. G., & Geyer, M. A. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-01-00305.2001 · Cited by 271 · cited 2×
“2003; Tamminga 2006), but the disruptive effects of D1 receptors are not consistently observed and likely dependent on dopaminergic tone (Ralph et al. 2001; Ralph-Williams et al. 2002; Tanda et al. 2009).”
Cited by
Dopamine and glutamate in schizophrenia: biology, symptoms and treatment
McCutcheon, R. A., Krystal, J. H., & Howes, O. D. (2020) · World Psychiatry · doi:10.1002/wps.20693 · Cited by 612
DISC1: Structure, Function, and Therapeutic Potential for Major Mental Illness
Soares, D. C., Carlyle, B. C., Bradshaw, N. J., & Porteous, D. J. (2011) · ACS Chemical Neuroscience · doi:10.1021/cn200062k · Cited by 129
Livingston, N. R., Hawkins, P. C., Gilleen, J., Ye, R., Valdearenas, L., Shergill, S. S., & Mehta, M. A. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211000778 · Cited by 17
“In the previous studies, only a single dose of roflumilast was given, so the most likely mechanism for an effect was an increase in excitatory neurotransmission (Kuroiwa et al., 2012).”
Background
Metadata
- Authors
- Kuroiwa, M., Snyder, G. L., Shuto, T., Fukuda, A., Yanagawa, Y., Benavides, D. R., Nairn, A. C., Bibb, J. A., Greengard, P., & Nishi, A.
- Venue
- Psychopharmacology
- Published
- 2011-08-11
- Volume
- 219
- Issue
- 4
- Pages
- 1065-1079
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2023858737
- Cited by
- 64
- References
- 12
- FWCI
- 1.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phosphodiesterase 4 inhibition enhances the dopamine D1 receptor/PKA/DARPP-32 signaling cascade in frontal cortex. https://app.cochat.ai/papers/10.1007/s00213-011-2436-8
- The paper
- Kuroiwa, M., Snyder, G. L., Shuto, T., Fukuda, A., Yanagawa, Y., Benavides, D. R., Nairn, A. C., Bibb, J. A., Greengard, P., & Nishi, A. (2012). Phosphodiesterase 4 inhibition enhances the dopamine D1 receptor/PKA/DARPP-32 signaling cascade in frontal cortex. Psychopharmacology. https://doi.org/10.1007/s00213-011-2436-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.